Therapeutics Targeting Mutant KRAS.

  title={Therapeutics Targeting Mutant KRAS.},
  author={Kyaw Zin Thein and Amadeo B Biter and David S. Hong},
  journal={Annual review of medicine},
Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switches and functions and triggering intracellular signaling cascades such as the MAPK, and PI3K pathways. Of the three RAS isoforms expressed in human cells, all of which were linked to tumorigenesis more than three decades ago, KRAS is the most… 

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

The mutations and functions of KRAS in human tumors are outlined and then indirect and direct approaches to shut down the oncogenic KRAS network are analyzed, including mechanistic principles, clinical features, and strategies for overcoming primary or secondary resistance to KRAS-G12C blockade.

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

The most recent advances in therapeutic approaches and resistance mechanisms targeting KRAS mutations and opportunities for combination therapy are reviewed.

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design

The presented review article mainly summarizes the developments of small molecule KRAS inhibitors as drug candidates and rational approaches that are being utilized for the selective targeting of KRAS signaling in the mutant cancer cells.

Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021)

This review covers the recent patents (2019–2021) on KRASG12C inhibitors, which are mostly highlighted in terms of chemical structures, molecular mechanisms of action, pharmacokinetic properties, and potential clinical applications.

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

The importance of various types of mechanism-based pharmaceutical models in evaluation of different types of MET-targeting therapeutics and the advantages and disadvantages of these mechanism- based strategies for SMKIs, conventional TMABs, and antibody-based biotherapeutics are analyzed.

Role of RAS signaling in ovarian cancer

The RAS family of proteins is among the most frequently mutated genes in human malignancies and the involvement of oncogenic RAS in mediating carcinogenesis and chemoresistance in OC and its subtypes is showcased.

Targeting the undruggable oncogenic KRAS: the dawn of hope

Recent KRAS-targeting strategies, their therapeutic potential, and remaining challenges to overcome are reviewed and the potential synergistic effects of various combinatorial therapies in preclinical and clinical trials are highlighted.

Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

Analysis of the preclinical rationale for combining the MAPK pathway and autophagy and the most recent clinical trials that have been launched to capitalize on this potentially synthetic lethal approach to cancer therapy are provided.

Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells

This work isolates a small molecule that interacts with a hydrophobic surface at the boundary of Igf2bp1 KH3 and KH4 domains, and inhibits binding to Kras RNA, and presents an avenue for improving the prognosis of IgF2BP1-expressing tumours in lung, and potentially other, cancer(s).

Role of RAS signaling in ovarian cancer [version 1; peer review: awaiting peer review]

Recent literature showcasing the involvement of oncogenic RAS in mediating carcinogenesis and chemoresistance in OC and its subtypes is reviewed, suggesting that OCCC harbor distinct molecular with respect to other EnOC.